The Core Facility Nanobodies and the Institute of Experimental Oncology receive funding from BONFOR Instrument 9 for the development of a novel Nanobody screening-platform
In March 2022, the Core Facility Nanobodies together with Prof. Tobias Bald…
Control hub for skin inflammation discovered
Study by the University of Bonn identifies new signaling pathway to combat UV damage and infections Inflammatory reactions in the skin can reduce damage from UV radiation or infections, but can also result in painful symptoms such as sunburn. A recent study at the University of Bonn and the University Hospital Bonn has now identified…
Elevator helps bacteria to build an invisibility cloak
Study: Bacterial membrane transporter helps pathogens to hide from immune system The transport of substances across the membrane into the cell is linked to specific membrane transport proteins. Researchers at the University Hospital Bonn (UKB) and the University of Bonn, in collaboration with an international team, have now succeeded in elucidating the molecular structure of…
New approach against chronic inflammation
Researchers at the Universities of Bonn and Sao Paulo have succeeded in mitigating chronic inflammation in mice using customized “mini-antibodies.” These nanobodies enabled them to dissolve molecular complexes in tissue that normally activate the immune system. The nanobodies produced may in future…
Molecule attacks coronavirus in a novel way
Active ingredient inhibits infection with so-called pseudoviruses in the test tube, as shown by study at the University of Bonn Scientists at the University of Bonn and the caesar research center have isolated a molecule that might open new avenues in the fight against SARS coronavirus 2. The active ingredient binds to the spike protein…
New promising antibodies against SARS-CoV-2
Study in Science: Combination of two molecules simultaneously attacks multiple sites on the surface of the virus An international research team led by the University of Bonn has identified and further developed novel antibody fragments against the SARS coronavirus-2. These “nanobodies” are much smaller than the classic antibodies used to treat US President Donald Trump,…